We have 3 of 29 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Expanding TCV catch-up vaccination eligibility beyond 15 years up to age 35 years provides additional public health benefit in some settings, and is cost-saving in very-high-incidence settings and in drug-resistant scenarios, and cost-effective in high-incidence settings where case fatality and costs of illness are hig...
Persistent fluoroquinolone resistance, particularly among S. Typhi and S. Paratyphi A populations in Nepal, underscores ongoing AMR challenges and highlights the need for expanded vaccine strategies targeting both pathogens.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
